经济观察网归创通桥发布正面盈利预告，预期2025年净利润超过人民币2.4亿元，同比增长约139.4%， 营收超过10.5亿元，同比增长约34.6%。根据港股规则，公司需在近期内披露经审计的完整年度报告。 产品研发进展 通桥麒麟血流导向装置、ZYLOX Swan静脉导管等产品2025年销售表现强劲，且颈动脉双层密网支架等 创新产品已进入国家药监局"绿色通道"。新产品获批上市及现有产品在集采环境下的放量情况可能成为 市场焦点。 股票近期走势 受盈喜及国际化进展催化，2026年2月3日公司股价单日涨近7%，成交额达1788万港元。若业绩正式报 告超预期或战略布局传出新进展，可能进一步影响短期市场情绪。 以上内容基于公开资料整理，不构成投资建议。 业绩经营情况 归创通桥于2026年1月29日发布正面盈利预告，预期2025年净利润超过人民币2.4亿元，营收超过10.5亿 元。根据港股规则，盈喜后公司需在近期内披露经审计的完整年度报告，具体时间可能于2026年3月前 公布。 业务进展情况 2026年1月，公司宣布战略收购德国Optimed公司，以加速欧洲市场渗透；截至2025年底，其销售渠道已 覆盖83个国家，海外收入同 ...

Core Viewpoint - Guichuang Tongqiao Medical Technology Co., Ltd. has officially launched its innovative medical base in Zhuhai, Guangzhou, focusing on the development and manufacturing of neuro-interventional products, aiming to stand out in a highly competitive market through unique "micro-innovations" and a comprehensive product portfolio [1][5]. Group 1: Company Overview - The newly opened Tongqiao Medical Innovation Base integrates R&D, high-end manufacturing, and industrialization [1]. - The company has developed a unique "weaving" technology for its nickel-titanium alloy stents, which are used for treating brain aneurysms [1]. - Guichuang Tongqiao currently offers the most comprehensive range of neuro and peripheral vascular interventional medical devices among domestic companies, with 73 products in total, of which 51 have been approved for sale in China [5]. Group 2: Production and Capacity - The production line is currently operating at full capacity, with plans to increase production capacity by seven to eight times once the new base is fully operational [2]. - Most core components are self-manufactured, and the company is enhancing quality stability and product yield through automation [2]. - The company has experienced significant growth in overseas orders, indicating strong demand for its products [2]. Group 3: Market Trends and Opportunities - The neuro-interventional market in China is expected to grow to 37.1 billion yuan by 2030, with the number of related surgeries projected to reach 881,300 [3]. - The domestic market has seen a shift towards local products due to high prices of foreign alternatives, creating opportunities for local companies [3]. - Guichuang Tongqiao has benefited from multiple rounds of centralized procurement since 2022, which has facilitated rapid product adoption in hospitals [6][7]. Group 4: Innovation Strategy - The company focuses on "micro-innovations" to differentiate itself in a crowded market, with recent innovations including a unique stent design that minimizes damage to blood vessel walls [4]. - Guichuang Tongqiao has several products in the pipeline, including the first domestic dual-layer carotid stent and a self-expanding aneurysm embolization device [4]. Group 5: International Expansion - The company is actively pursuing international markets, with 22 products commercialized in 27 countries and over 31 products undergoing registration in 23 countries [7]. - Guichuang Tongqiao has established strategic partnerships with over 60 global companies and is preparing for further international expansion through potential acquisitions [8].

Core Insights - Guichuang Tongqiao won the "Annual Investment Value Award" at the "Jingge Award Annual Excellence Company Ceremony" due to its solid performance, forward-looking strategic layout, and outstanding innovation capabilities [1] - The award reflects the structural opportunities in the high-value medical device industry and the company's competitive strength [1] Industry Overview - The high-value medical device industry is currently experiencing a development window characterized by innovation upgrades and internationalization [2] - Policies are increasingly incentivizing innovation, enhancing growth certainty in the industry, and empowering leading innovative device companies [3] - Recent regulatory measures have optimized approval processes for high-end medical devices, significantly shortening the time to market [3] - The normalization of centralized procurement has reduced the impact on market expectations, allowing for reasonable profit margins for innovative products [3] Company Performance - Guichuang Tongqiao's performance in 2025 has exceeded market expectations, with revenue reaching 482 million yuan, a year-on-year increase of 31.7%, and net profit of 121 million yuan, up 76% [6][7] - The company initiated its first cash dividend since its listing, planning to distribute a total of 32.47 million yuan, reflecting a payout ratio of 32.4% [6] - The company has a diverse product portfolio with 73 products and projects, including 52 approved by NMPA and 8 with EU CE certification, establishing a "one-stop" solution in the vascular intervention field [7] Global Expansion - Guichuang Tongqiao's international business revenue grew by 36.9% in the first half of 2025, with products sold in 27 countries and regions, including entry into 7 of the top 10 global markets [8] - The company is expanding its presence in key European markets and emerging markets like Brazil, India, and South Africa, indicating significant growth potential in overseas markets [8] Investment Outlook - The investment value of Guichuang Tongqiao has been widely recognized by professional institutions, with several brokerages raising their ratings and target prices [10] - The company is positioned as a leader in domestic substitution and a participant in the global market, with its growth potential being increasingly acknowledged [10]

Core Insights - The article highlights the approval of eight innovative medical devices by NMPA, indicating a growing trend in the medical technology sector in China [1] Company Summaries - **瑞石心禾（河北）医疗科技有限公司**: Established in July 2022, this company focuses on high-end medical equipment and innovative nuclear drug development, aiming to assist in early diagnosis and precision treatment of major diseases like cancer and cardiovascular issues [2] - **飞光视觉科技（南京）有限公司**: Founded in 2022, this company specializes in femtosecond laser technology for ophthalmic surgeries and has a strong research foundation from Huazhong University of Science and Technology [3] - **南京广慈医疗科技有限公司**: Established in 2013, this company focuses on ultrasound therapy devices for non-invasive treatment of hypertension and metabolic syndrome, showcasing a successful integration of academia and industry [6] - **上海术济客医疗科技有限公司**: This company is dedicated to the intelligentization of minimally invasive surgeries for structural heart diseases, combining robotic technology with catheter-based procedures [7] - **健诺维（成都）生物科技有限公司**: Founded in May 2020, this company specializes in regenerative medicine for ophthalmology, with its core product being the first approved wet preserved amniotic membrane in China [9] - **北京谱德生物科技有限公司**: Established in May 2021, this company focuses on molecular diagnostics and genetic testing, holding multiple patents in related technologies [10] - **深圳市纬康医疗科技有限公司**: Founded in October 2023, this company specializes in vascular intervention consumables and has already received approvals for multiple medical devices [11] - **通桥医疗科技有限公司**: Established in February 2016, this company focuses on high-end neurovascular interventional medical devices and has a wide sales network covering over 3,000 hospitals in China [12]